Everand Logo

Welcome to Everand!

  • STAT

    Opinion: ‘Deep medicine’ will help everyone, especially people like me with a rare disease

    AI won't replace doctors but will free them up to operate at the apex of their professional mission: humanistic interactions and relationships with those in their care.
    by Yoni Maisel Apr 26, 2019 5 minutes

    Two things I read recently gave me hope for the future of medicine and the future of people like me with rare or difficult-to-diagnose diseases.

    One was the article “Calculation of a Primary Immunodeficiency ‘Risk Vital Sign’ via Population-Wide Analysis of Claims Data to Aid in Clinical Decision Support” in the journal Frontiers in Pediatrics. Not a sexy title, I know, but stick with me here. The other was Eric Topol’s newest book, “Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again.”

    These two related works resonated with me because I have a rare disease called . In this mostly genetic disorder, protective antibodies are either seriously lacking or entirely absent, leaving individuals susceptible to all types of infections, many of which have the potential to become life-threatening. This dearth of antibodies also leads

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
    A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
    Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.

    Related